FDA Stressing Statistical Outcomes Over Standardization In Imaging Trials
Executive Summary
FDA is emphasizing statistical outcomes over protocol standardization when assessing imaging studies, according to Division of Medical Imaging Drug Products Director George Mills
You may also be interested in...
President’s Budget Paves The Critical Path With $6 Mil. Request
FDA requests $6 mil. and six FTEs for its Critical Path initiative in fiscal 2007, marking the first time funding has been proposed for the program
President’s Budget Paves The Critical Path With $6 Mil. Request
FDA requests $6 mil. and six FTEs for its Critical Path initiative in fiscal 2007, marking the first time funding has been proposed for the program
Exploratory INDs Will Better Serve Large Companies, PDL Exec Says
Exploratory investigational new drug applications will provide a greater benefit to large pharma and biotech companies, Protein Design Labs CEO Mark McDade said at the Biotechnology Industry Organization Windhover conference in Washington, D.C. April 26